Glioblastoma—the most aggressive form of brain cancer—remains one of medicine's biggest challenges. Despite surgery, ...
Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Prelimi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback